法国复杂腹主动脉瘤开窗或分支血管内修复的真实世界两年结果
本研究比较法国医保数据库(SNDS)1073例与前瞻性临床研究186例接受开窗或分支血管内主动脉修复(fbEVAR)的复杂腹主动脉瘤患者中期结果。SNDS与临床研究30天死亡率分别为5.5%与4.3%,两年全因死亡免除率分别为80.0%与85.1%,动脉瘤相关死亡免除率分别为93.8%与94.6%。作者认为医保数据库或可作为长期随访和上市后监测的替代。
要点
- SNDS与临床研究两年全因死亡免除率分别为80.0%与85.1%,动脉瘤相关死亡免除率分别为93.8%与94.6%。
- SNDS两年二次干预免除率为73%,临床研究为79.1%。
- 临床研究两年动脉瘤稳定或缩小者占92.3%,所有内脏靶血管一期通畅丧失免除率高于95%。
核心结论
- SNDS与临床研究的真实世界结果提示高危人群复杂腹主动脉瘤fbEVAR术后中期结果良好。
- 两项研究结果相似,提示医保数据库或可作为前瞻性临床研究用于长期随访和上市后监测的替代。
研究设计与样本
- 法国两项真实世界研究:一项为回顾性医保数据库研究(SNDS),提取2012年4月至2018年12月所有使用研究器械治疗患者的植入和/或随访期间住院数据,共1073例。
- 另一项为前瞻性临床研究,2016年12月至2018年11月连续纳入法国15家中心接受研究器械fbEVAR的高危患者186例。
主要发现
- SNDS与临床研究平均年龄分别为71.9岁与71.8岁,男性分别为91.0%与89.8%,30天死亡率分别为5.5%与4.3%。
- SNDS与临床研究使用定制开窗或分支器械者分别为80.7%与96.2%,使用CE标记Zenith Fenestrated器械者分别为19.3%与3.8%,初始或技术成功率均高于94%。
- SNDS与临床研究两年全因死亡免除率分别为80.0%与85.1%,动脉瘤相关死亡免除率分别为93.8%与94.6%。
- SNDS两年二次干预免除率为73%;临床研究两年动脉瘤稳定或缩小者占92.3%,所有内脏靶血管一期通畅丧失免除率高于95%,二次干预免除率为79.1%。
关键数值与推荐
- SNDS研究两年全因死亡免除率80.0%,动脉瘤相关死亡免除率93.8%,二次干预免除率73%。
- 临床研究两年全因死亡免除率85.1%,动脉瘤相关死亡免除率94.6%,二次干预免除率79.1%,动脉瘤稳定或缩小者92.3%。
临床怎么用
- 作者认为,医保数据库的使用或可作为前瞻性临床研究用于长期随访和上市后监测的替代。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To describe and compare mid-term outcomes from 2 real-world data collection efforts on fenestrated and branched endovascular aortic repair (fbEVAR) for complex abdominal aortic aneurysms (AAAs) in France and to evaluate the potential of health care databases for long-term post-market surveillance (PMS) and continued reimbursement approval. METHODS: Two real-world studies were conducted in France: a retrospective health care database study (SNDS) and a prospective clinical study. In the SNDS study, data from implantation and/or hospital stays occurring during follow-up were extracted for all patients treated with the study devices from April 2012 to December 2018. In the clinical study, high-risk patients undergoing fbEVAR with the study devices were enrolled consecutively at 15 sites in France from December 2016 to November 2018. RESULTS: Data from 1073 patients were extracted from SNDS and compared with analogous variables from 186 patients in the clinical study. Most demographic details were similar between studies (SNDS vs clinical: mean age, 71.9 vs 71.8 years; men, 91.0% vs 89.8%), as was 30-day mortality (SNDS: 5.5%, clinical: 4.3%). Patients received custom-made fenestrated or branched devices (SNDS: 80.7%, clinical: 96.2%) or CE-marked Zenith Fenestrated devices (SNDS: 19.3%, clinical: 3.8%). Initial or technical success was above 94% for both studies. Two-year freedom from all-cause mortality was 80.0% (SNDS) and 85.1% (clinical study). Two-year freedom from aneurysm-related mortality was 93.8% (SNDS) and 94.6% (clinical study). Detailed imaging outcomes were not captured within SNDS; however, information on secondary procedures to restore patency was available and used as a surrogate measure for secondary interventions. Two-year freedom from secondary interventions was 73% for the SNDS study. In the clinical study, at 2 years, aneurysm stability or shrinkage was observed in 92.3% of patients, freedom from target vessel primary patency loss was above 95% for all visceral target vessels, and freedom from secondary interventions was 79.1%. CONCLUSION: Real-world outcomes from the SNDS and clinical study suggest positive mid-term outcomes in high-risk populations following fbEVAR for complex AAAs. The similarities between these studies suggest that the use of health care databases may be an alternative to prospective clinical studies for long-term follow-up and PMS.Clinical ImpactPositive results following endovascular repair of complex abdominal aortic aneurysms are observed from data extracted from both the French health care database and a post-market clinical study despite initial high-risk patient status and diverse center experience. These outcomes parallel more rigorously designed studies and suggest that with careful study design, real-world data collections have high translatable value to add to the clinical understanding of fenestrated and branched endovascular aortic repair (fbEVAR).
引用
- Haulon S, Steinmetz E, Feugier P, et al. Two-Year Results on Real-World Fenestrated or Branched Endovascular Repair for Complex Aortic Abdominal Aneurysm in France. J Endovasc Ther. 2023. PMID: 37902436. doi:10.1177/15266028231208653
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。